

Literatur für onkologie heute 6/2020

SCHWERPUNKT: GASTROINTESTINALE TUMOREN

Das Frühkarzinom am ösophagogastralen Übergang: Indikationen zur endoskopischen und chirurgischen Resektion (S. 22–29)

J.-O. Jung, M. K. Diener, A. Schaible, B. P. Müller-Stich, T. Schmidt

1. Leitlinienprogramm Onkologie. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. AWMF-Registernummer: 032/009OL. (https://www.awmf.org/uploads/tx_szleitlinien/032-009L_S3_Magenkarzinom_Diagnostik_Therapie_Adenokarzinome_oesophagogastraler_Uebergang_2019-12.pdf). Zugegriffen: 10.02.2020
2. Leitlinienprogramm Onkologie. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. AWMF-Registernummer: 021/023OL. (https://www.awmf.org/uploads/tx_szleitlinien/021-023OL_Plattenepithel_Adenokarzinom_Oesophagus_2019-01.pdf). Zugegriffen: 10.02.2020
3. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. *J Gastric Cancer* 2019; 19: 1–48
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; 20: 1–19
5. Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the Esophagus and Esophagogastric Junction – Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. *CA Cancer J Clin* 2017; 67: 304–317
6. Murakami T. Early cancer of the stomach. *World J Surg* 1979; 3: 685–692
7. Azari FS, Roses RE. Management of Early Stage Gastric and Gastroesophageal Junction Malignancies. *Surg Clin North Am* 2019; 99: 439–456
8. Schuhmacher C, Novotny A, Feith M, Friess H. Die neue TNM-Klassifikation der Tumoren des ösophagogastralen Übergangs. Chirurgische Konsequenzen. *Chirurg* 2012; 83: 23–30.
9. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Hoboken: Wiley-Blackwell; 2017
10. Park CH, Park JC, Chung H, Shin SK, Lee SK, Lee YC. A specific role of endoscopic ultrasonography for therapeutic decision-making in patients with gastric cardia cancer. *Surg Endosc* 2016; 30: 4193–4199
11. D’Journo XB, Thomas PA. Current management of esophageal cancer. *J Thorac Dis* 2014; 6 (Suppl 2): S253–S264
12. Guo HM, Zhang XQ, Chen M, Huang SL, Zou XP. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. *World J Gastroenterol* 2014; 20: 5540–5547
13. Sun F, Yuan P, Chen T, Hu J. Efficacy and complication of endoscopic submucosal dissection for superficial esophageal carcinoma: a systematic review and meta-analysis. *J Cardiothorac Surg* 2014; 9: 78
14. Abdelfatah MM, Barakat M, Lee H, Kim JJ, Uedo N, GrimmI, Othman MO. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis. *Gastrointest Endosc* 2018; 87: 338–347
15. Buskens CJ, Westerterp M, Lagarde SM, Bergman JJ, ten Kate FJ, van Lanschot JJ. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. *Gastrointest Endosc* 2004; 60: 703–710

16. Westerterp, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJ, Bergman JJ, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. *Virchows Arch* 2005; 446: 497–504
17. Bollschweiler, Baldus SE, Schröder W, Prenzel K, Gutschow C, Schneider PM, Hölscher AH. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. *Endoscopy* 2006; 38: 149–156
18. Badreddine RJ, Prasad GA, Lewis JT, Ltzke LS, Borkenhagen LS, Dunagan KT, Wang KK. Depth of Submucosal Invasion Does Not Predict Lymph Node Metastasis and Survival of Patients With Esophageal Carcinoma. *Clin Gastroenterol Hepatol* 2010; 8: 248–253
19. Sepesi B, Watson TJ, Zhou D, Polomsky M, Litle VR, Jones CE, et al. Are Endoscopic Therapies Appropriate for Superficial Submucosal Esophageal Adenocarcinoma? An Analysis of Esophagectomy Specimens. *J Am Coll Surg* 2010; 210: 418–427
20. Hölscher AH, Bollschweiler E, Schröder W, Metzger R, Gutschow C, Drebber U. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. *Ann Surg* 2011; 254: 802–808
21. Griffin SM, Burt AD, Jennings NA. Lymph node metastasis in early esophageal adenocarcinoma. *Ann Surg* 2011; 254: 731–737.
22. Lorenz D, Origer J, Pauthner M, Graupe F, Fisseler-Eckhoff A, Stolte M, et al. Prognostic risk factors of early esophageal adenocarcinomas. *Ann Surg* 2014; 259: 469–476
23. Pyo JH, Lee H, Min YW, Min BH, Lee JH, Kim KM, et al. Indication for endoscopic treatment based on the risk of lymphnode metastasis in patients with Siewert type II/III early gastric cancer. *Gastric Cancer* 2018; 21: 672–679
24. Gertler R, Stein HJ, Schuster T, Rondak IC, Höfler H, Feith M. Prevalence and topography of lymph node metastases in early esophageal and gastric cancer. *Ann Surg* 2014; 259: 96–101
25. Manner H, Pech O, Heldmann Y, May A, Pauthner M, Lorenz D, et al. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. *Surg Endosc* 2015; 29: 1888–1896
26. Manner H, Wetzka J, May A, Pauthner M, Pech O, Fisseler-Eckhoff A, et al. Early-stage adenocarcinoma of the esophagus with mid to deep submucosal invasion (pT1b sm2–3): the frequency of lymph-node metastasis depends on macroscopic and histological risk patterns. *Dis Esophagus* 2017; 30: 1–11
27. Bogoevski D, Bockhorn M, Koenig A, Reeh M, von Loga K, Sauter G, et al. How radical should surgery be for early esophageal cancer? *World J Surg* 2011; 35: 1311–1320
28. Zapletal C, Heesen C, Origer J, Pauthner M, Pech O, Ell C, Lorenz D. Quality of life after surgical treatment of early Barrett's cancer: a prospective comparison of the Ivor-Lewis resection versus the modified Merendino resection. *World J Surg* 2014; 38: 1444–1452
29. Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. *Gut* 2008; 57: 1200–1206
30. Kim HJ, Chung H, Shin SK, Kim HI, Park JC, Lee SK, et al. Comparison of long-term clinical outcomes between endoscopic and surgical resection for early-stage adenocarcinoma of the esophagogastric junction. *Surg Endosc* 2018; 32: 3540–3547
31. Gong EJ, Kim DH, Ahn JY, Jung KW, Lee JH, Choi KD, et al. Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. *Gastric Cancer* 2017; 20 (Suppl 1): 84–91
32. Filip B, Scarpa M, Cavallin F, Alfieri R, Cagol M, Castoro C. Minimally invasive surgery for esophageal cancer: a review on sentinel node concept. *Surg Endosc* 2014; 28: 1238–1249

Therapiealgorithmus beim Adenokarzinom des Magens (S. 30–34)

B. Sonnweber, E. Wöll

1. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al.; GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a metaanalysis. *JAMA* 2010; 303: 1729–1737
2. Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Landi L, Santoro A, et al. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. *J Clin Oncol* 2012; 30 (Suppl 18): LBA 4001
3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; 345: 725–730
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al.; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; 355: 11–20
5. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD 07-FFCD 9703 trial. *J Clin Oncol* 2007; 25 (Suppl 18): 4510
6. Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. *Lancet Oncol* 2017; 18: 1249–1260
7. Al-Batran S-E, Homann N, Schmalenberg H, Kopp H-G, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. *J Clin Oncol* 2017; 35 (Suppl 15): 4004
8. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al.; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012; 366: 2074–2084
9. Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al.; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. *Lancet Oncol* 2018; 19: 616–628
10. Leong T, Smithers BM, Haustermans K, Michael M, GebSKI V, Miller D, et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. *Ann Surg Oncol* 2017; 24: 2252–2258
11. Park SH, Lee SJ, Kim ST, Lee J, Park JO, Park YS, et al. Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2). *J Clin Oncol* 2015; 33 (Suppl 3): TPS228
12. Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by

- surgery versus neoadjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. *BMC Cancer* 2018; 18: 877
13. Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. *Lancet Oncol* 2017; 18: 357–370
 14. Al-Batran S-E, zur Hausen G. FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (RAMSES/FLOT7). NCT02661971. (<https://clinicaltrials.gov/ct2/show/NCT02661971>). Zugegriffen: 30.10.2019
 15. Al-Batran S-E. FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (PETRARCA). NCT02581462. (<https://clinicaltrials.gov/ct2/show/NCT02581462>). Zugegriffen: 30.10.2019
 16. Wagner AD. Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION). NCT02205047. (<https://clinicaltrials.gov/ct2/show/NCT02205047>). Zugegriffen: 31.10.2019
 17. Lordick F, Arnold D, Borner M, Bruns CJ, Eisterer W, Faber G, et al. Onkopedia Leitlinien. Magenkarzinom. (<https://www.onkopedia.com/de/onkopedia/guidelines/magenkarzinom/@@guideline/html/index.html>) . Zugegriffen: 31.10.2019
 18. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. *J Clin Oncol* 2006; 24: 2903–2909
 19. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Eur J Cancer* 2011; 47: 2306–2314
 20. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. *J Clin Oncol* 2012; 30: 1513–1518
 21. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol* 2013; 31: 4438–4444
 22. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al.; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014; 15: 78–86
 23. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al.; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 2014; 383: 31–39
 24. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al.; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014; 15: 1224–1235
 25. Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran S-E, Van Cutsem E, et al. RAINFALL: A randomized, doubleblind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with

- metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. *J Clin Oncol* 2018; 36 (Suppl 4): 5
26. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; 376: 687–697
 27. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 2018; 19: 1372–1384.
 28. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in Combination With Capecitabine plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC – A Randomized Phase III Trial. *J Clin Oncol* 2016; 34: 443–451
 29. Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, openlabel, adaptive, phase 2/3 study. *Lancet Oncol* 2017; 18: 640–653
 30. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the secondline treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN – a randomized, phase III study. *J Clin Oncol* 2014; 32: 2039–2049
 31. Makiyama A, Sagara K, Kawada J, Kashiwada T, Hosokawa A, Horie Y, et al. A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. WJOG7112G (T-ACT). *J Clin Oncol* 2018; 36 (Suppl 15): 4011
 32. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2018; 19: 1437–1448
 33. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastroesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebocontrolled, phase 3 trial. *Lancet* 2017; 390: 2461–2471
 34. Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* 2018; 24: 1449–1458
 35. Al-Batran S-E, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. *BMC Cancer* 2017; 17: 893